

## **Cadila Healthcare Limited**


### **Investor Presentation**

March 2018



### **A Leading Pharmaceutical Company**







4. As of March 26, 2018

### Vertically Integrated Business Model with Presence Across The Pharma Value Chain



APIs	Generics and Niche Generics	Specialty and Branded Business <sup>(1)</sup>	Biologics and Vaccines	NCEs
<ul> <li>Selective backward integration</li> <li>Niche API supply to key clients</li> <li>220+ scientists</li> <li>132 active DMFs filed with USFDA <sup>2</sup></li> </ul>	<ul> <li>Increased focus on niche categories (Transdermal, Nasals, Modified Release Oral Solids, Topicals etc.)</li> <li>725+ scientists</li> <li>Total 323 ANDAs filed (as of Dec 31, 2017)</li> <li>90+ para IV filings</li> <li>Generating &gt;85% revenues from formulations business across India, U.S. and other markets</li> </ul>	<ul> <li>Focus on pain management, dermatology and oncology products</li> <li>Development of 505(b)(2) opportunities</li> <li>Entered into a partnership to launch. Zypitamag TM (Pitavastatin Magnesium tablets), the first product filed through 505(b)(2) route</li> <li>Acquisition of Sentynl Therapeutics Inc., specializing in pain management</li> </ul>	<ul> <li>Biologics: 21 biosimilars (pipeline and launched) and 6 novel products (pipeline) <sup>2</sup></li> <li>9 launched in India; 4 in Emerging Markets</li> <li>Exemptia<sup>™</sup> (1<sup>st</sup> biosimilar of Adalimumab) in India</li> <li>100+ scientists,</li> <li>Vaccines: 19 under development (including 7 where marketing authorization has been received)</li> <li>4 vaccines launched</li> <li>~ 50 scientists</li> <li>Dedicated, separate facilities for biologics and vaccines</li> </ul>	<ul> <li>NCEs: 3 NCEs (2 new and 1 existing for new indications)</li> <li>1<sup>st</sup> NCE in India developed in-house by the company: Lipaglyn® (Saroglitazar)</li> <li>Received marketing approval in Mexico for Lipaglyn <sup>™</sup> for 2 indications</li> <li>Phase II trials going on in US for 3 indications of Lipaglyn®</li> <li>280+ scientists</li> <li>Strong scientific advisory board</li> <li>Dedicated research facility</li> </ul>
		managomont		



### **Key Business Segments**






	Key Formulations Businesses	Other Businesses & Alliances	Emerging Businesses
Divisions	<ul> <li>India formulations</li> <li>#4 by value<sup>1</sup></li> <li>4.2% market share<sup>1</sup></li> <li>US formulations</li> <li>#9 by prescription volumes<sup>2</sup></li> <li>3.04% market share<sup>2</sup></li> <li>Latin America</li> <li>Emerging Markets of Asia and Africa</li> </ul>	<ul> <li>EU Formulations</li> <li>Consumer Wellness</li> <li>Animal Health</li> <li>APIs</li> <li>JVs &amp; alliances</li> </ul>	<ul><li>Biologics</li><li>Vaccines</li><li>NCEs</li></ul>
Key Themes	<ul> <li>Sustainable and profitable growth</li> <li>Significant revenue contribution</li> </ul>	Growth potential in Wellness and Animal Health segments	<ul> <li>Innovative technology with high entry barriers for competition</li> </ul>
In-House Capabilities serving as bedrock of organization	32 manufacturing facilities across India, US, Brazil and Germany Manufacturing	8 R&D sites across India, US and Italy 1350+ scientists R&D Capabilities	Highly experienced and qualified management team People



### **Track Record of Value Creation**







Market capitalization is calculated by applying the closing price of the financial year



### **Key Business Segments**






#### **Our US Formulations Business**

- #9 generics player in US (based on prescriptions) with a market share of 3.04%<sup>1</sup>
  - Among top 3 players by prescription in all of top 10 products marketed in the US (Source: IMS Health, IMS National Sales Perspective Audit, MAT January 2018 and IMS National Prescription Audit, January 2018)
- Sale of generic oral solids and injectable products; 100+ products commercialized
- Strong product pipeline
  - 141 ANDAs pending approval (of which 59 Para IV filings)
- Cost efficient manufacturing and supply chain
- Relationships with key wholesalers and retail pharmacy chains
- Entered into a partnership to launch Zypitamag ™ (Pitavastatin Magnesium tablets), the first product filed through 505 (b)(2) route.
- Acquired Sentynl Therapeutics Inc., a US based specialty pharmaceutical company, specializing in pain management segment in Fiscal 2017







# Strong Filing Track Record and Addition to Capabilities



**Growing Focus on Complex Generics Business** 







### Large ANDA Pipeline With Increasing Focus on **Niche Filings**



#### Approved ANDAs by Type

Nasals

2

Orals -

Modified

Release

38

Topicals

5

As on 31 December 2017

Injectables

9

Oral

Suspension-

1


Orals -Controlled

Substance

8



As on 31 December 2017





### **Strong Leadership in India Formulations Business**



#### Leading Player in the \$18 Bn Market of India<sup>1</sup>








- 1. Source: AWACS MAT December 2017
- 2. FY15 financials as per IGAAP; FY16, FY17 and 9M FY18 financials as per IND AS
- Excludes ~1,450 managers
- 4. US\$ 1 = INR 64.5
- 5. Source: AWACS

### Focus on Key Therapeutic Areas in India





Leadership positions (top 3) in Dermatology, Pain Management, Gynecology, Respiratory and Cardiology

Trademark acquisitions to fill the portfolio gaps –acquired trademarks from MSD in men's and women's health

Introduction of biologicals and vaccines products

In-licensing arrangements

Improving field force productivity



# Represents Zydus' ranking in the promoted covered market

### **Other Growing Formulations Markets**



Latin America		Emerging Markets	
Zydus Size <sup>2</sup>	c.US\$ 39 MM	Zydus Size <sup>2</sup>	
Zydus Growth	~6%	Zydus Growth	
<ul> <li>Two large pharmac</li> </ul>	eutical markets in Latin America	<ul> <li>Branded generics a</li> </ul>	ınd g
<ul> <li>Branded generics a</li> </ul>	nd generic generics	One of the leading	com
• Brazil: 80+ filings, 4	45 approvals, ~40 products being sold	Launched 4 biosimi	ilars
Mexico: 45 filings,	40 approvals, 20+ products commercialized	<ul> <li>Continue to expand markets</li> </ul>	lgeo
<ul> <li>Focused segments</li> </ul>	(Branded) – CVS, central nervous system,		
female healthcare,	hepatology and nutraceuticals	<ul> <li>Leveraging existing</li> </ul>	por

Emerging Markets		
	Emerging Markets in Asia and Afri	
Zydus Size <sup>2</sup>	c.US\$ 80 MM	
Zydus Growth	~5%	
Branded generics and	d generic generics	
One of the leading co	mpanies in several of these markets	
Launched 4 biosimilar	rs	
Continue to expand geographical presence in select emerging		

- Continue to expand geographical presence in select emerging markets
- Leveraging existing portfolio of India and other regulated markets



### **Other Businesses**









#### Value Creation Through Win-win Alliances and Be a Partner of Choice

#### Zydus Takeda JV

- 50:50 JV with Takeda Pharmaceuticals
- Currently manufacturing complex high-end APIs of Takeda
- Commercial supply of 11 products

#### Zydus Hospira JV

- 50:50 contract manufacturing JV with Hospira<sup>1</sup> for cytotoxic injectable products
- State-of-the-art cytotoxic facility which is inspected by leading authorities like MHRA, USFDA, TGA etc.
- Manufactured 15 products which are sold primarily in US and EU

#### **Bayer Zydus JV**

- 50:50 JV with Bayer
- Operates in female healthcare, metabolic disorders, diagnostics, CVS, anti-diabetics and oncology segments in India
- Leveraging strengths of Bayer's optimised product portfolio and Zydus' marketing and distribution capabilities
- JV scope covers launch of innovator products of Bayer in India

#### **Other Alliances**

- 26 ANDAs filed, 19 approved (for partners)
- Out-licensing deal with Abbott for supply of 24 products (with an option to include 39 additional products)
- Out-licensing and distribution arrangements for biosimilars in certain emerging markets like Turkey, Russia, Indonesia and Columbia





### Manufacturing and Innovation



### Strong Base of Cost Efficient and State-of-the-Art Manufacturing Facilities





17 facilities for formulations, 4 for API, 3 for vaccines, 3 for biologics, 3 for consumer wellness and 2 for animal health

Capabilities across platforms - Oral Solids, Controlled Substances, Injectables, Topicals, Lyophilized Injectable, Sprays and Transdermals


Focus on quality, efficiency and regulatory compliance



### **Key Focus Areas for R&D**



#### R&D expenditure formed ~8%<sup>1</sup> of total operating revenues





Vaccines

**NCEs** 

indications)

### **Capabilities in Complex Segments**



#### Biologics

- 21 biosimilars (pipeline and launched) and 6 novel products (pipeline)
  - Launched 9 products in India and 4 in Emerging Markets
  - Launched Exemptia<sup>™</sup> (biosimilar of Adalimumab) – 1<sup>st</sup> company in India<sup>1</sup>
  - Received Marketing Authorization for 2 more products
  - 2 products already in clinical development phase
  - Development of RabiMabs in collaboration with WHO
- Wide range of indications covered including oncology, nephrology, ophthalmology, infectious diseases, osteoporosis, inflammation

#### Vaccines

- Launched 4 products, received marketing authorizations for 7 other
  - First Indian company to launch indigenously developed and manufactured H1N1 vaccine – VaxiFlu-S<sup>1</sup>
- 19 under development (including 7 where marketing authorization has been received)

#### NCEs

- Launched Lipaglyn<sup>®</sup> in India 1<sup>st</sup> NCE developed by the company, for 2 indications (Diabetic Dyslipidemia and Hypertriglyceridemia)
- Received marketing approval in Mexico for Lipaglyn <sup>TM</sup> for 2 indications (Diabetic Dyslipidemia and Hypertriglyceridemia)
  - Phase III trials ongoing in India for 3 indications (Lipodystrophy, NASH<sup>2</sup>, Type 2 Diabetes)
  - Phase II trials ongoing in US for 3 indications (NASH<sup>2</sup>, PBC<sup>3</sup> and Hypertriglyceridemia)
- 2 other NCE molecules under various stages of development
  - ZYH7 (Dyslipidemia)
  - ZYAN1 (Anemia)






### **Key Financials**





### **Financial Profile**












#### Leverage (Net Debt / EBITDA)<sup>2</sup>





1. US\$1 = INR 64.5

2. FY15 financials as per IGAAP; FY16, FY17 and 9M FY18 financials as per INDAS and hence not comparable

3. ROE = PAT / average of opening and closing net worth; ROCE = (Profit after tax + Finance cost net of tax) / average of opening and closing (net worth + gross debt)

### Key Financial Numbers – Q3 FY18



Consolidated (US\$ Mio.) <sup>1</sup>	Amount	Gr.%
Total Income from Operations	505	37.9%
EBIDTA	130	108.1%
EBIDTA % to Total Income from Ops.	25.8%	
Profit before tax	112	122.5%
PBT % to Total Income from Ops.	22.1%	
Net Profit	84	67.7%
Net Profit % to Total Income from Ops.	16.7%	
R&D Spend % to Total Income from Ops.	6.4%	
Debt net of cash (as at 31-Dec-17)	558	
Capex (Apr – Dec 17)	108	



### **Strategies For The Future**







### **Building Blocks For Our Strategy**



Regulatory Compliance and Quality	<ul> <li>Focus on best in class manufacturing</li> <li>People training</li> <li>QUEST: Quality Excellence by Sustainable Transformation; Institutionalising a Culture of Quality</li> </ul>
Operational Excellence	<ul> <li>PRISM – cost optimization program adopted in 2002 and institutionalised across the group</li> <li>SLIM - a Strategic, Lean and Integrated Manufacturing initiative</li> </ul>
Innovate For Growth	<ul> <li>Continue to replenish generic pipeline in the US with profitable opportunities – move towards specialty</li> <li>In the branded generics / specialty markets of India and other emerging market to focus on additional growth from more advanced areas like biologics</li> <li>Continue to invest behind, innovate and commercialize opportunities in biologics, vaccines and NCEs</li> <li>Near term focus on emerging markets with longer term potential in developed markets</li> </ul>
M&A	<ul> <li>Selective M&amp;A</li> <li>Complimentary generic assets or technology platforms</li> <li>Specialty or branded assets</li> <li>Consolidation / leadership</li> </ul>





## **Thank You**

#### DISCLAIMER AND SAFE HARBOUR STATEMENT

THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF CADILA HEALTHCARE LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY").

The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares.

This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment income (vi) cash flow projections etc.

The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates.

This document is just a Presentation and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the Company's equity shares. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from.

This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This document and its contents should not be forwarded or delivered or transmitted in any manner to any person other than its intended recipient, and should not be reproduced in any manner whatsoever.

